Leerink Partnrs Brokers Reduce Earnings Estimates for Waters

Waters Co. (NYSE:WAT) – Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for shares of Waters in a research report issued to clients and investors on Wednesday, February 12th. Leerink Partnrs analyst P. Souda now anticipates that the medical instruments supplier will earn $2.21 per share for the quarter, down from their prior forecast of $2.45. The consensus estimate for Waters’ current full-year earnings is $11.79 per share. Leerink Partnrs also issued estimates for Waters’ Q1 2025 earnings at $2.21 EPS, Q4 2025 earnings at $4.42 EPS, Q4 2025 earnings at $4.42 EPS, FY2025 earnings at $12.84 EPS, FY2026 earnings at $14.05 EPS and FY2026 earnings at $14.05 EPS.

Waters (NYSE:WAT) last released its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 EPS for the quarter, beating the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 49.93% and a net margin of 21.43%.

Several other research firms also recently commented on WAT. Barclays raised Waters from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $360.00 to $415.00 in a report on Monday, February 10th. TD Cowen increased their price target on Waters from $363.00 to $410.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft increased their price target on Waters from $310.00 to $325.00 and gave the company a “hold” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. increased their price target on Waters from $340.00 to $380.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Finally, Stifel Nicolaus increased their price target on Waters from $332.00 to $360.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Ten research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $390.40.

Waters Trading Up 1.9 %

NYSE WAT opened at $376.73 on Monday. The company has a market cap of $22.37 billion, a PE ratio of 35.95, a PEG ratio of 7.37 and a beta of 1.01. The company has a current ratio of 2.02, a quick ratio of 1.38 and a debt-to-equity ratio of 1.14. Waters has a 12 month low of $279.24 and a 12 month high of $423.56. The stock has a 50 day moving average of $389.12 and a 200-day moving average of $365.09.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd bought a new position in shares of Waters in the fourth quarter worth $28,000. Kennebec Savings Bank bought a new position in shares of Waters in the third quarter worth $33,000. Bank of Jackson Hole Trust bought a new position in shares of Waters in the fourth quarter worth $34,000. Fortitude Family Office LLC increased its position in shares of Waters by 235.7% in the fourth quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 66 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Waters by 129.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 53 shares during the period. Institutional investors own 94.01% of the company’s stock.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.